SNGX Panoramica delle azioni Soligenix, Inc. è una società biofarmaceutica in fase avanzata di sviluppo e commercializzazione di prodotti per il trattamento di malattie rare negli Stati Uniti. Maggiori dettagli
Premi Analisi del rischio + 2 più rischi
Vedi tutti gli assegni di rischio Catturate i vostri pensieri, i link e la narrativa aziendale
Soligenix, Inc. Concorrenti Storia dei prezzi e prestazioni
Riepilogo dei massimi, dei minimi e delle variazioni dei prezzi delle azioni per Soligenix Prezzi storici delle azioni Prezzo attuale dell'azione US$2.89 Massimo di 52 settimane US$19.20 Minimo di 52 settimane US$1.83 Beta 1.75 Variazione di 1 mese -13.08% Variazione a 3 mesi -23.14% Variazione di 1 anno -76.15% Variazione a 3 anni -98.18% Variazione a 5 anni -99.17% Variazione dall'IPO -99.99%
Notizie e aggiornamenti recenti
Soligenix, Inc. Initiates Confirmatory Phase 3 Clinical Trial of HyBryte for the Treatment of Cutaneous T-Cell Lymphoma Dec 16
Soligenix, Inc. Announces Formation of European Medical Advisory Board for Cutaneous T-Cell Lymphoma Nov 20
Soligenix Initiates A Phase 2 Clinical Trial of SGX945 (Dusquetide) for the Treatment of Behcet's Disease Nov 14
Third quarter 2024 earnings released: US$0.78 loss per share (vs US$2.56 loss in 3Q 2023) Nov 10
Soligenix, Inc. Announces HyBryte Expanded Treatment Results to Be Presented at the European Organisation for Research and Treatment of Cancer Conference Oct 07
Consensus revenue estimates decrease by 28%, EPS upgraded Aug 16 Vedi altri aggiornamenti
Soligenix, Inc. Initiates Confirmatory Phase 3 Clinical Trial of HyBryte for the Treatment of Cutaneous T-Cell Lymphoma Dec 16
Soligenix, Inc. Announces Formation of European Medical Advisory Board for Cutaneous T-Cell Lymphoma Nov 20
Soligenix Initiates A Phase 2 Clinical Trial of SGX945 (Dusquetide) for the Treatment of Behcet's Disease Nov 14
Third quarter 2024 earnings released: US$0.78 loss per share (vs US$2.56 loss in 3Q 2023) Nov 10
Soligenix, Inc. Announces HyBryte Expanded Treatment Results to Be Presented at the European Organisation for Research and Treatment of Cancer Conference Oct 07
Consensus revenue estimates decrease by 28%, EPS upgraded Aug 16
Price target decreased by 13% to US$35.00 Aug 12
Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind Aug 11
Soligenix, Inc. Announces Significant Progress in the Treatment of Cutaneous T-Cell Lymphoma with its Investigational Drug, HyBryte™ Aug 02
Soligenix, Inc. Announces an Interim Update on the Open-Label, Investigator-Initiated Study Evaluating Extended HyBryte Treatment for Up to 12 Months in Patients with Early-Stage Cutaneous T-Cell Lymphoma Jul 10
Soligenix, Inc. Announces Positive Clinical Results from A Comparative Study Evaluating Hybryte™? Against Valchlor®? in the Treatment of Cutaneous T-Cell Lymphoma Jun 25
Soligenix, Inc. Announces Positive Clinical Results from HyBryte Compatibility Study in the Treatment of Cutaneous T-Cell Lymphoma May 18
Consensus revenue estimates decrease by 13%, EPS upgraded May 17
Price target decreased by 29% to US$2.50 May 15
First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind May 13
Soligenix, Inc., Annual General Meeting, May 23, 2024 May 01
Soligenix Extends Patent Protection for Its Filovirus Vaccine Platform to the United Kingdom and South Africa Apr 27
Consensus EPS estimates upgraded to US$0.63 loss Apr 25
Price target increased by 7.7% to US$3.50 Apr 12
Soligenix Announces Agreement on the Design of Second Confirmatory Placebo-Controlled Trial for Hybryte™ with the European Medicines Agency Apr 04
Consensus revenue estimates decrease by 11%, EPS upgraded Mar 22
Full year 2023 earnings: EPS and revenues exceed analyst expectations Mar 17
No longer forecast to breakeven Mar 17
Soligenix, Inc. Announces Formation of Behçet's Disease Medical Advisory Board Feb 08
FDA Grants Soligenix "Fast Track" Designation for Dusquetide in the Treatment of Oral Lesions of Behçet's Disease Jan 09
Soligenix Announces Top-Line Results of the Phase 2A Study of Sgx302 (Synthetic Hypericin) in Patients with Mild-To-Moderate Psoriasis Jan 05
Soligenix Announces Publication Demonstrating Complete Protection Against Filovirus Disease in Nonhuman Primate Models of Ebola and Marburg Viruses Jan 02
Soligenix Receives Written Notice from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Rule and Not Eligible for Second 180 Day Period Dec 24
New major risk - Share price stability Dec 01
Soligenix, Inc. Receives FDA IND Clearance for Phase 2 Clinical Trial of Dusquetide in Treatment of Aphthous Ulcers in Behçet's Disease Nov 30
Consensus EPS estimates upgraded to US$0.83 loss, revenue downgraded Nov 20
Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind Nov 16
Price target decreased by 35% to US$3.25 Nov 14
Insufficient new directors Nov 14
Soligenix, Inc. Announces HyBryte(TM) Expanded Treatment Trial in Cutaneous T-Cell Lymphoma Opens Enrollment Aug 11
Soligenix, Inc., Annual General Meeting, Sep 21, 2023 Aug 08
Soligenix Announces Expansion of SGX302 (Synthetic Hypericin) Phase 2a Study in Mild-to-Moderate Psoriasis Jul 12
Timothy R. Coté Resigned as A Member of the Board of Directors of Soligenix, Inc Jul 10
Consensus revenue estimates increase by 13% May 31
Soligenix Regains Compliance with the Shareholders’ Equity Requirement and in Compliance with All Other Applicable Requirements for Listing on Nasdaq May 29
First quarter 2023 earnings: EPS and revenues exceed analyst expectations May 18
Soligenix, Inc. Announces Scheduling of Type A Meeting with the U.S. FDA to Review Proposed Study Design for a Second Phase 3 Study Evaluating HyBryte(TM) in the Treatment of Cutaneous T-Cell Lymphoma May 12
Soligenix Announces Positive Clinical Results from Compatibility Study of HyBryte in the Treatment of Cutaneous T-Cell Lymphoma May 05
Soligenix, Inc. Announces Appointment of Timothy R. Coté, M.D. to Its Board of Directors May 04
No longer forecast to breakeven Apr 08
Consensus revenue estimates decrease by 76%, EPS upgraded Apr 06
No longer forecast to breakeven Apr 04
Soligenix, Inc. Receives Refusal to File Letter from U.S. FDA for Hybryte™ New Drug Application in the Treatment of Cutaneous T-Cell Lymphoma Feb 15
Soligenix Announces Publication Demonstrating Positive Correlates of Protection with Rivax® in Non-Human Primate Survival After Ricin Challenge Dec 21
Soligenix, Inc. Initiates Phase 2 Clinical Trial of SGX302 (Synthetic Hypericin) for the Treatment of Mild-To-Moderate Psoriasis Dec 20
Soligenix Announces Submission of New Drug Application to the FDA for Hybryte™ in the Treatment of Cutaneous T-Cell Lymphoma Dec 16
Soligenix Receives Non Compliance Notice from Nasdaq Nov 21
Insufficient new directors Nov 17
Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind Nov 13
Soligenix: A Biotech Bargain Ready To File For Approval In Cutaneous T-Cell Lymphoma Oct 05
U.S. FDA awards $2.6M grant for expanded study of Soligenix's HyBryte for skin cancer Sep 12
Soligenix, Inc. Announces U.S. Food and Drug Administration Awards $2.6 Million Orphan Products Development Grant for Expanded Study of HyBryte in the Treatment of Cutaneous T-Cell Lymphoma Sep 07
Soligenix announces $2.6M FDA grant to further study blood cancer candidate Sep 06
Is Soligenix (NASDAQ:SNGX) Using Debt Sensibly? Sep 06
Second quarter 2022 earnings: EPS and revenues exceed analyst expectations Aug 13
Soligenix GAAP EPS of -$0.06 beats by $0.03, revenue of $0.4M beats by $0.2M Aug 12
Soligenix, Inc., Annual General Meeting, Sep 22, 2022 Aug 06
Soligenix, Inc. Receives Agreement from FDA on Initial Pediatric Study Plan for HyBryte for the Treatment of Cutaneous T-Cell Lymphoma Jul 28
Soligenix, SERB Pharma team up to develop therapy for ricin poisoning Jul 25
Soligenix, Inc. Announces HyBryte™ Phase 3 FLASH Study for the Treatment of Cutaneous T-Cell Lymphoma Published in JAMA Dermatology Jul 21
Soligenix, Inc. Receives FDA IND Clearance for Phase 2 Clinical Trial of Synthetic Hypericin in Treatment of Psoriasis Jun 29
Soligenix Announces Successful Protection Using A Bivalent Thermostabilized Filovirus Vaccine Jun 24
Soligenix Receives US Patent Allowance for Its Thermostabilized Vaccine Platform May 24
Price target decreased to US$3.88 May 20
First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind May 14
Insufficient new directors Apr 27
Is Soligenix (NASDAQ:SNGX) Using Debt Sensibly? Apr 22
Consensus forecasts updated Apr 05
No longer forecast to breakeven Apr 02
Full year 2021 earnings: EPS and revenues exceed analyst expectations Mar 30
Soligenix, Inc. Demonstrates Positive Anti-Tumor Efficacy in Multiple Nonclinical Animal Studies Jan 05
Is Soligenix (NASDAQ:SNGX) Using Too Much Debt? Jan 03
Forecast to breakeven in 2024 Jan 01
Third quarter 2021 earnings released: US$0.088 loss per share (vs US$0.061 loss in 3Q 2020) Nov 15
Soligenix Announces Accelerated Publication Demonstrating Efficacy and Broad Neutralizing Activity of Its Covid-19 Vaccine in Non-Human Primates Oct 01
Shareholders May Find It Hard To Justify Increasing Soligenix, Inc.'s (NASDAQ:SNGX) CEO Compensation For Now Sep 17
Health Check: How Prudently Does Soligenix (NASDAQ:SNGX) Use Debt? Aug 30
Soligenix Shares Preclinical Data Demonstrating That Its Thermostable Vaccine Platform May Be an Important Contributor to Addressing the Next Potential Pandemic and Future Health Emergencies Aug 25
Soligenix, Inc. Announces Publication Demonstrating Successful Formulation and Heat Stabilization of Filovirus Vaccine Platform for Ebola and Marburg Virus Diseases Aug 24
Consensus forecasts updated Aug 20
Price target decreased to US$3.75 Aug 18
Second quarter 2021 earnings released: US$0.047 loss per share (vs US$0.10 loss in 2Q 2020) Aug 18
Soligenix, Inc. announced delayed 10-Q filing May 19
First quarter 2021 earnings released: US$0.064 loss per share (vs US$0.32 loss in 1Q 2020) May 19
Soligenix, Inc. Plans to Submit Nda May 08
Is Soligenix (NASDAQ:SNGX) Weighed On By Its Debt Load? May 08
Consensus revenue estimates fall to US$1.07m Apr 06
Full year 2020 earnings released: US$0.64 loss per share (vs US$0.48 loss in FY 2019) Apr 01
What Type Of Returns Would Soligenix's(NASDAQ:SNGX) Shareholders Have Earned If They Purchased Their SharesFive Years Ago? Mar 16
Soligenix, Inc. Announces Positive Progress in the Pre-clinical Development of its COVID-19 Vaccine Mar 06
Soligenix Receives Hong Kong Patent for Therapeutic Use of Synthetic Hypericin to Treat Cutaneous T-Cell Lymphoma Feb 02 Rendimenti per gli azionisti SNGX US Biotechs US Mercato 7D -2.0% 0.7% 0.6% 1Y -76.1% -3.4% 23.8%
Vedi i rendimenti completi degli azionisti
Ritorno vs Industria: SNGX ha avuto una performance inferiore rispetto al US Biotechs che ha registrato un rendimento -3.4 % nell'ultimo anno.
Rendimento vs Mercato: SNGX ha avuto una performance inferiore al mercato US che ha registrato un rendimento 23.8 % nell'ultimo anno.
Volatilità dei prezzi Is SNGX's price volatile compared to industry and market? SNGX volatility SNGX Average Weekly Movement 12.5% Biotechs Industry Average Movement 10.7% Market Average Movement 6.3% 10% most volatile stocks in US Market 17.6% 10% least volatile stocks in US Market 3.1%
Prezzo delle azioni stabile: Il prezzo delle azioni di SNGX è stato volatile negli ultimi 3 mesi.
Volatilità nel tempo: La volatilità settimanale di SNGX è diminuita da 41% a 12% nell'ultimo anno, ma è comunque superiore al 75% delle azioni US.
Informazioni sull'azienda Fondato I dipendenti AMMINISTRATORE DELEGATO Sito web 1987 14 Christopher Schaber www.soligenix.com
Soligenix, Inc. è una società biofarmaceutica in fase avanzata di sviluppo e commercializzazione di prodotti per il trattamento di malattie rare negli Stati Uniti. L'azienda opera attraverso due segmenti, Specialized BioTherapeutics e Public Health Solutions. Il segmento Specialized BioTherapeutics sviluppa SGX301 (HyBryte), una nuova terapia fotodinamica, che ha completato la Fase III di sperimentazione clinica per il trattamento del linfoma cutaneo a cellule T; SGX942, una tecnologia regolatrice della difesa innata che è in Fase III di sperimentazione clinica per il trattamento di malattie infiammatorie, tra cui la mucosite orale nel cancro della testa e del collo; SGX302, una tecnologia IDR in fase IIa per il trattamento della psoriasi da lieve a moderata, e SGX945 e una tecnologia IDR in fase IIa per il trattamento delle ulcere aftose nella malattia di Behçet.
Mostra di più Soligenix, Inc. Riepilogo dei fondamenti Come si confrontano gli utili e i ricavi di Soligenix con la sua capitalizzazione di mercato? SNGX statistiche fondamentali Capitalizzazione di mercato US$7.25m Guadagni(TTM ) -US$7.10m Ricavi(TTM ) US$364.18k
Guadagni e ricavi Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM) SNGX Conto economico (TTM ) Ricavi US$364.18k Costo del fatturato US$340.92k Profitto lordo US$23.27k Altre spese US$7.12m Guadagni -US$7.10m
Ultimi guadagni dichiarati
Sep 30, 2024
Prossima data di guadagno
n/a
Utile per azione (EPS) -2.83 Margine lordo 6.39% Margine di profitto netto -1,949.32% Rapporto debito/patrimonio netto 34.7%
Come si è comportato SNGX nel lungo periodo?
Vedi performance storica e confronto
Analisi aziendale e situazione dei dati finanziari Dati Ultimo aggiornamento (ora UTC) Analisi dell'azienda 2024/12/27 10:53 Prezzo dell'azione a fine giornata 2024/12/27 00:00 Guadagni 2024/09/30 Guadagni annuali 2023/12/31
Fonti dei dati I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC . I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
Pacchetto Dati Tempistica Esempio Fonte USA * Dati finanziari della società 10 anni Conto economico Rendiconto finanziario Bilancio Stime di consenso degli analisti +3 anni Previsioni finanziarie Obiettivi di prezzo degli analisti Prezzi di mercato 30 anni Prezzi delle azioni Dividendi, scissioni e azioni Proprietà 10 anni Top azionisti Insider trading Gestione 10 anni Team di leadership Consiglio di amministrazione Sviluppi principali 10 anni
* esempio per i titoli statunitensi, per quelli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più , cliccate qui .
Modello di analisi e Snowflake I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github ; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube .
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su .
Fonti analitiche Soligenix, Inc. è coperta da 6 analisti. 2 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
Analista Istituzione James Molloy Alliance Global Partners Jonathan Aschoff Brean Capital Andrew D'Silva B. Riley Securities, Inc.
Mostra 3 altri analisti 
